Comparison of the Efficacy and Safety of Warfarin and Antiplatelet Therapy in Patients with Atrial Fibrillation and End-Stage Renal Disease
10.3904/kjm.2019.94.2.191
- Author:
Donghee HAN
1
;
Jae Sun UHM
;
Jung Tak PARK
;
Tae Hoon KIM
;
Boyoung JOUNG
;
Tae Hyun YOO
;
Hui Nam PAK
;
Shin Wook KANG
;
Moon Hyoung LEE
Author Information
1. Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea. mhlee@yuhs.ac
- Publication Type:Original Article
- Keywords:
Atrial fibrillation;
Kidney failure, Chronic;
Anticoagulants;
Warfarin
- MeSH:
Anticoagulants;
Atrial Fibrillation;
Follow-Up Studies;
Hemorrhage;
Humans;
Kidney Failure, Chronic;
Male;
Medical Records;
Platelet Aggregation Inhibitors;
Retrospective Studies;
Warfarin
- From:Korean Journal of Medicine
2019;94(2):191-199
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: The optimal strategy for anticoagulation treatment in patients with atrial fibrillation (AF) and end-stage renal disease (ESRD) has not been established. We evaluated the efficacy and bleeding risk of warfarin and antiplatelet agents in patients with AF and ESRD. METHODS: We retrospectively reviewed the medical records of 256 patients with AF and ESRD and included 158 patients (age, 63.7 ± 12.2 years; male sex, n = 103) with a CHA2DS2-VASc score ≥ 1 who were taking warfarin (n = 53) or an antiplatelet agent (n = 105). RESULTS: During the follow-up period (31.0 ± 29.4 months), 10 ischemic events and 29 major bleeding events occurred. The thromboembolic event rate did not significantly differ between the warfarin and antiplatelet groups (1.9% and 8.6%, respectively; p = 0.166). However, the rate of major bleeding events was significantly higher in the warfarin group than it was in the antiplatelet group (32.1% and 11.4%, respectively; p = 0.002). Cox's regression analysis indicated that warfarin was related to an increased risk of major bleeding events (hazard ratio [HR], 3.44; 95% confidence interval [CI], 1.60–7.36; p = 0.001). Conversely, warfarin was not related to a decreased risk of thromboembolic events (HR, 0.34; 95% CI, 0.04–2.70; p = 0.306). CONCLUSIONS: In patients with AF and ESRD, warfarin use was associated with an increased risk of bleeding events, compared with antiplatelet agents.
